Related Experiment Video

Updated: Jun 11, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?

Catherine C Parker1, Fred Ampil, Gary Burton

  • 1Department of Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, USA.

Surgery
|June 29, 2010
PubMed
Abstract

Insights

Breast conservation therapy (BCT) is a viable option for selected triple-receptor negative breast cancers (TNBC). This aggressive cancer can be managed with BCT, showing comparable outcomes to mastectomy in specific patient groups.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Breast Cancer Research

Background:

  • Triple-receptor negative breast cancer (TNBC) is an aggressive malignancy lacking ER, PR, and HER2 expression.
  • Limited comparative data exists for breast conservation therapy (BCT) versus mastectomy in TNBC.
  • This study investigates the hypothesis that BCT is a feasible management option for TNBC.

Purpose of the Study:

  • To compare the oncological outcomes of breast conservation therapy (BCT) versus mastectomy in patients with triple-receptor negative breast cancer (TNBC).
  • To evaluate the impact of surgical approach on recurrence rates and survival in TNBC.
  • To identify predictors of disease-free survival and overall survival in TNBC patients.

Main Methods:

  • Retrospective analysis of 202 patients with TNBC treated with either BCT or mastectomy.
  • Primary endpoints included cancer recurrence (local, regional, distant) and death.
  • Statistical analyses employed Kaplan-Meier, log-rank, t-tests, Cox proportional hazards models, and Chi-square tests.

Main Results:

  • BCT was utilized in 30% of patients. Isolated local recurrence was significantly lower in the BCT group (0%) compared to mastectomy (10.6%, P=.02).
  • No significant differences were observed in regional or distant recurrence rates between BCT and mastectomy groups.
  • While 5-year overall survival favored BCT (89% vs 69%), multivariate analysis indicated surgical approach did not impact disease-free survival or OS; tumor stage (T-stage, N-stage) were independent predictors.

Conclusions:

  • Breast conservation therapy (BCT) is a viable and safe surgical option for selected patients with triple-receptor negative breast cancer (TNBC).
  • Careful patient selection is crucial, considering tumor stage and other prognostic factors.
  • BCT can achieve comparable oncological safety to mastectomy for appropriately selected TNBC patients.

More Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction13:35

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...